Opens in a new tab

Promosome v BioNTech (CFI, 3 April 2025)

Date3 April 2025
CourtCFI
DivisionMunich (DE) Local Division
Type of actionProcedural Order
Registry referenceApp_11376/2025 · ORD_11610/2025
PartiesBioNTech Manufacturing Marburg GmbH , BioNTech Manufacturing GmbH , BioNTech SE, BioNTech Europe GmbH , BioNTech Innovative Manufacturing S…

Official decision (PDF) · UPC registry entry

Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.

Contact the firm

Dhenne Avocats · 10 October 2026

Our analysis

Summary

By order of 3 April 2025 (UPC_CFI_846/2024, ORD_11610/2025 and ORD_11611/2025), Judge-rapporteur Kupecz of the Munich Local Division rejected the applications to produce evidence filed on 7 March 2025 by the five BioNTech companies and the four Pfizer companies, defendants to Promosome LLC’s infringement action on EP 2 401 365. They sought, under penalty, the detailed materials and methods and the raw data behind the qPCR experiments in Exhibit VB 6. A single document decides both applications (Nos 11376/2025 and 11372/2025), which were identical in substance.

Question

May a party obtain, under Rule 190 RoP, the raw data behind experiments relied on by its opponent without first contesting the facts those experiments establish?

Decision

The defendants did not state which fact they intended to prove, had not specifically contested the facts drawn from Exhibit VB 6 or raised concrete defences the evidence would support, a prior step under Rule 24(e) to (g) RoP, and offered no reasonably available and plausible evidence for their defence. Whether the evidence was sufficiently specified under Rule 190.1 RoP was doubtful but left open. The front-loaded nature of the proceedings does not oblige the claimant to file all underlying data at this stage, since the parties determine their own evidence (Art. 43 UPCA). Production may still be ordered later (Rules 190 and 172.2 RoP) or clarification sought (Rule 9.1 RoP). The penalty request fell with the main request. Panel review remains available (Rule 333 RoP).

Key points for practice

Provisions applied

Agreement on a Unified Patent Court
Arts 43, 59(1) and 82(4)
Rules of Procedure
Rules 9.1, 24, 172.2, 190.1 and 333
Directive 2004/48/EC
Art. 6(1)
Case law cited
Guangdong OPPO v Panasonic, Court of Appeal, 24 September 2024, Winnow Solutions v Orbisk, The Hague Local Division, 14 October 2024, Dish v Aylo, Mannheim Local Division, 20 October 2024

Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.


Going further

Lexicon: Written procedure (UPC), Court fees and costs (UPC).

Source and translations

Official source
Unified Patent Court registry link recorded in the record
Original language
not recorded
Translation available
no translation recorded the firm’s French record is a summary, not a translation
Date checked
not recorded
Only the official text is authoritative. A machine translation is never presented as official, republishing a third-party document requires a verified basis in rights, and a link to the source is preferred.

Follow this case

Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.

Proceedings

No case number recorded in this record.

Parties

Exact name as it appears in the record, group affiliation only where sourced and dated.

Decisions in the same proceedings and documented appeals

No other decision in the corpus bears the same case number, and no appeal is documented in the corpus to date.

What the record states

Nature of the act
Procedural Order
Outcome (Dhenne Avocats summary)
Les demandes de BioNTech et Pfizer tendant à la production des données brutes des expériences qPCR de Promosome sont rejetées comme irrecevables ou, en tout cas, mal fondées.
Appeal
No appeal documented in the corpus, this does not mean that no appeal was lodged.
Instance
First-instance decision, whether it has become final is not recorded.

Patents mentioned

Related decisions cited in the analyses

Scope: Dhenne Avocats corpus. Registry-based links are marked “official number”; links derived from the analyses are marked as such. An erroneous link can be withdrawn without deleting any record.

Patents and standards

PublicationRole in the disputeFamilyStandard and declarationPoolSources
EP 2 401 365
Reengineering mrna primary structure for enhanced protein production
recorded proprietor: Scripps Research Institute
Mentioned in the analysis (role not qualified)
Also mentioned in 6 other decision(s): Promosome v BioNTech (CFI, UPC_CFI_846/2024, 7 July 2026) · Promosome v BioNTech (CFI, 15 July 2025) · Promosome v BioNTech (CFI, 17 April 2025) · Promosome v BioNTech (CFI, 9 April 2025) · Promosome v BioNTech (CFI, 10 March 2025) · Promosome v BioNTech (CoA, 12 October 2026)
not recordednot recordednot recordedEspacenet · European Patent Register
existence and title of the publication checked on 30 October 2026 (Google Patents, Espacenet and Register links are not checked automatically)
mentioned in: Dhenne Avocats analysis
The statuses “asserted in litigation”, “declared essential”, “listed by a pool” and “essentiality examined by a court” are distinct and may coexist. Validity, infringement and technical essentiality are different questions. Scope: patents cited in the decisions of the Dhenne Avocats corpus, with no essentiality score or prediction.

Receive an alert

Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.

Follow

Weekly summary, on Fridays.